Erythrodermic psoriasis improved by panitumumab, but not bevacizumab

Acta Derm Venereol. 2012 Jul;92(4):360-1. doi: 10.2340/00015555-1348.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab
  • Dermatitis, Exfoliative / diagnosis
  • Dermatitis, Exfoliative / drug therapy*
  • Dermatitis, Exfoliative / etiology
  • Humans
  • Male
  • Panitumumab
  • Psoriasis / complications
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Rectal Neoplasms / complications
  • Rectal Neoplasms / diagnosis
  • Rectal Neoplasms / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab
  • Panitumumab